What Factors Propelled The Growth Of The Head And Neck Cancer Therapeutics Market In The Past?
The head and neck cancer therapeutics market has seen considerable growth due to a variety of factors.
•The market size for therapeutics in head and neck cancer has seen significant growth in the past few years. Predictions suggest that it will expand from $1.71 billion in 2024 to $1.9 billion in 2025, representing a compound annual growth rate (CAGR) of 11.3%.
Factors contributing to this growth during the historic period include tobacco and alcohol use, infections from the human papillomavirus (HPV), environmental exposure, and the evolution of treatment techniques.
What Is The Projected Growth And Market Size For The Head And Neck Cancer Therapeutics Sector?
The head and neck cancer therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of therapeutics for head and neck cancer is projected to experience swift expansion in the coming years, with an expected value of $2.85 billion in 2029 and a compound annual growth rate of 10.6%.
The predicted growth during this forecast period is a result of advancements in immunotherapy, the introduction of precision medicine, increased awareness, early detection campaigns, and the worldwide aging population. Significant trends during this period are likely to include a larger focus on targeted therapies, greater use of less invasive surgical methods, integration of comfort care, research into new biomarkers, and models of care that prioritize the patient.
What Are The Core Factors Supporting Growth In The Head And Neck Cancer Therapeutics Market?
The head and neck cancer therapeutics market is set to grow with the rising occurrence of head and neck cancers. This type of cancer originates from an uncontrolled growth of cells in the tissues of the head and neck area. The surge in these cases necessitates improved diagnosis and treatments, capable of addressing mutations and cancer cell irregularities. For instance, the UK’s independent cancer research institution, Cancer Research UK, anticipated in 2023, a 3% increase in head and neck cancer cases in the UK alone, from 2023 to 2025. Meanwhile, fatalities due to these cancers are forecasted to rise by 12% within the same period. Consequently, this escalating incidence of head and neck cancer fuels the expansion of the head and neck cancer therapeutics market.
What Are The Major Segments Within The Global Head And Neck Cancer Therapeutics Market?
The head and neck cancer therapeutics market covered in this report is segmented –
1) By Type: Programmed Cell Death (PD) Inhibitors, Microtubule Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors
2) By Route Of Administration: Injectable, Oral
3) By Distribution Channel: Retail And Specialty Pharmacies, Hospital Pharmacies, Online Pharmacies
4) By Application: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Other Applications
Subsegments:
1) By Programmed Cell Death (PD) Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors
2) By Microtubule Inhibitors: Taxanes, Vinca Alkaloids
3) By Epidermal Growth Factor Receptor (EGFR) Inhibitors: Monoclonal Antibodies, Tyrosine Kinase Inhibitors
Pre-Book The Head And Neck Cancer Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Head And Neck Cancer Therapeutics Market?
Major firms in the head and neck cancer therapeutics market are focusing their resources on the development and introduction of new medicinal treatments for patients diagnosed with head and neck cancer therapeutics. This encompasses the application of pharmaceutical compounds or medications to treat, manage, or ease ailments, diseases, or symptoms in people. To illustrate, Coherus BioSciences Inc., an American biopharmaceutical firm, earned FDA approval for its novel drug 'Loqtorzi', also known as toripalimab-tpzi, in October 2023. The approval was given for the drug to be used along with cisplatin and gemcitabine as the primary treatment for adults with diagnosed metastatic or recurrent, locally advanced nasopharyngeal carcinoma. The trial led to adverse reactions in less than 20% of patients, irrespective of whether the drug was used as a first-line treatment or as a single-agent therapy.
Who Are the Key Players in the Head And Neck Cancer Therapeutics Market?
Major companies operating in the head and neck cancer therapeutics market include:
• Pfizer Inc.
• F Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Sanofi Aventis LLC
• Bristol-Myers-Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline plc.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Incyte Corporation
• Ono Pharmaceutical Co. Ltd.
• Kyowa Kirin Co. Ltd.
• Hikma Pharmaceuticals PLC
• Clinigen Group plc.
• Ligand Pharmaceuticals
• Acceleron Pharma Inc.
• Taiho Pharmaceutical Co. Ltd.
• Boston Biomedical Inc.
• AB Science SA.
What Is The Most Dominant Region In The Head And Neck Cancer Therapeutics Market?
North America was the largest region in the head and neck cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the head and neck cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
